The study isolates, susceptibilities, typing results and clinical aspects.

ainterval (day) of the two isolates.bDefined by population analysis profile (PAP)–area under the curve (AUC) method (PAP-AUC) (see Materials and Methods).cNA, did not carry SCCmec.dThe duration of Vn exposure represents the total length of time that the patient received vancomycin.The VSSA isolate of each pair obtained prior to beginning vancomycin / teicoplanin therapy.eVAN, vancomycin; TEC, teicoplanin; OXA, oxacillin; LEV, levofloxacin; MFX, moxifloxacin; CIP, ciprofloxacin; IPM, imipenem; MEM, meropenem; AMK, amikacin; FEP, cefepime; CRO, ceftriaxone; CAZ, ceftazidime; CXM, cefuroxime; SCF, cefoperazone-sulbactam; TZP, piperacillin-tazobactam; RIF, rifampin; SXT, sulfamethoxazole-trimethoprim; LZD, linezolid.